SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO PHYSICIANS AT THE POINT-OF-CARE, OFFER AN IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLE THE DERIVATION OF PRACTICE-WIDE TREATMENT GUIDELINES

Author(s)

Schmeichel CJ1, Netherton DR2, 1SMA, Munster, IN, USA; 2InfoMedics International, Inc, Woburn, MA, USA

OBJECTIVES: Prospective 'real-world' patient experience data is a highly acceptable form of data that can be relevant to an individual clinician's practice in determining the optimal patient profile to achieve the most efficacious results. This study was designed to assess the real-world effectiveness of a sleeping medication and provide the treating physician with self-reported data to profile optimal patients for treatment. METHODS: Self-reported data about symptoms of transient insomnia and symptom relief prior to and after using a sleeping medication were collected from patients via telephone or the Internet. Treating physicians enrolled all patients and received individual patient reports. RESULTS: A total of 1378 patients completed both surveys. Ages were 39% < 45 and 43% between 45 and 64, and 77% were female. At baseline, 62% of patients reported having difficulty sleeping >14 nights per month. Factors creating periods of insomnia included stress (59%), depression/anxiety (39%), travel (3%), and work-related issues (3%). The most important quality in a sleeping medication was reported to be absence of 'grogginess' the following day (46%). The time required to get to sleep (15 to 60 minutes) improved for all study participants. With a statistical significance of p<0.001, reported symptoms of trouble falling asleep, not feeling rested, feeling sleepy the next day, and trouble functioning the next day were improved by 3 to 5 points on a 10-point scale. CONCLUSIONS: Findings suggest that the use of the study medication offers considerable relief of key symptoms. The findings also provide the practicing clinician with insights into the factors that patients require in a sleeping medication and suggest that effectiveness endpoints complement and even synergize with efficacy endpoints.

Conference/Value in Health Info

2003-11, ISPOR Europe 2003, Barcelona, Spain

Value in Health, Vol. 6, No. 6 (November/December 2003)

Code

PMD11

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Neurological Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×